From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)
Scenario
Incremental cost per QALY gained (% change from base case)
Base case
€ 15,574
Resistance adjustments
 No adjustments
€ 27,626 (+ 77%)
Second-line efficacy
 Assumed 100% response/cure rates in treatment
€ 30,614 (+ 97%)